• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Viewpoints

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Overcoming analytical challenges with chemical derivatization in LD-MS/MS

Learn about the challenges in chemical derivatization and utilizing LC-MS/MS to detect and quantify trace compounds in complex molecules for supporting bioanalytical studies.

Long acting injectables: Accelerating the path to patient wellbeing

Learn about the various challenges in developing LAIs and the technologies and techniques being used by Syngene to help clients use this transformative drug delivery system to treat chronic diseases.

Harnessing the immune system for cancer cell-therapy

Explore the top challenges in developing CAR-T therapy for treating cancer and how leading CRO-CDMO Syngene supports clients in bringing this therapy to patients faster.

Ensuring high-quality iPSCs to maximize drug discovery success

Learn the rigorous measures established at Syngene for tissue procurement, iPSC reprogramming, systematic cell banking, inventory management, and quality control of every iPSC batch to maximize drug discovery success.

Establishing the simple complex: Route to a successful large molecule bioanalytical sample analysis

Learn the simple and complex connections that must be established for successful large molecule bioanalytical sample analysis supporting clinical trials.

Navigating a smarter race: Lead to first-in-human studies

Learn the key strategies adopted by leading CDMO Syngene to accelerate the lead to first-in-human (FIH) journey of small molecules for clients.

Detection and quantitation of process-related impurities in biopharma manufacturing

Learn the challenges in the detection and quantitation of process-related impurities, including nitrosamine and azido impurities, and Syngene’s capabilities and solutions to resolve them.

Holistic, mechanism-driven approach to toxicity assessment using Computational and Data Sciences

Learn how Syngene provides in silico and in vitro support for holistic toxicity assessment using Computational & Data Sciences.

Regulatory role of Biophysics in Biologics CMC

Learn the role of biophysics-driven analytical tools in accurately identifying biologics CQAs and analyzing HOS to make the final product efficacious and safe for patients from a regulatory perspective.

Choosing the ‘right’ CRO-CDMO in Biopharma - What has changed

Learn the new criteria that have emerged as more important for selecting an outsourcing partner consequent to disruptions caused by the COVID-19 pandemic.

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details